Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Former Speaker of House joins pot advisory board!
The pot industry panicked when U.S. Attorney General Jeff Sessions ended the government’s hands-off policy on weed. Today, it can breathe a bit easier as former Republican House Speaker John Boehner joins the advisory board of U.S. cannabis producer Acreage Holdings.
“It is difficult to overstate the impact of this monumental event for the U.S. cannabis sector,” Vahan Ajamian, analyst at Beacon Securities Ltd., wrote in a note Wednesday.
The announcement that Boehner and former Massachusetts Governor William Weld will advise Acreage, a private company, “should send shockwaves throughout the industry and act as a positive catalyst for the sector as a whole,” Ajamian said.
Boehner’s move marks a fundamental shift for a man who said nine years ago he was “unalterably opposed” to legalization, and indicates that pot is increasingly supported by the American establishment even if the Attorney General still believes “good people don’t smoke marijuana.”
Pot stocks, many of which are listed in Canada because of U.S. legal uncertainty, have been struggling this year after nearly tripling in 2017. The BI Global Cannabis Competitive Peers index has lost more than one third of its value since the beginning of the year, partly spurred by Sessions’ move in January. Canada plans to legalize recreational use later this year -- following California’s steps to do so Jan. 1.
Ajamian believes U.S. cannabis producers “represent the next wave of outsized returns for investors” once the halo of legalization in Canada fades. Beacon calls Boehner’s appointment to Acreage’s advisory board a "bombshell" that may help "legitimize" the sector and generate investor interest.
https://www.msn.com/en-us/money/companies/boehners-bombshell-weed-reversal-a-big-boost-for-marijuana/ar-AAvLQIu
Great news farnorth! While you seem to "have their ear", so to speak, will you ask if they are going to release those new numbers immediately or wait for a quarterly report, etc?
I know they said news next week, but that news may just be that they fixed the packaging hiccup.
Please ask if they plan to provide the "big commitment" numbers as soon as they have the order. They are not great with promotion or direct answers, so while you have someone replying, please see if we can firm this up.
Thank you, Jim
Hi Surfgreen,
Thank you for sharing your source. Indeed, May 1st is now the completion date as pasted below.
With how far off other companies have been in forecasting study dates over the years, I am happy we are this close to May and they are holding that the completion date is the beginning of next month. This study is not the second coming, but it is one more piece of the puzzle coming together.
Study Start Date: November 2016
Estimated Study Completion Date: 1st of May 2018
I know some here have invested later than others and with a shorter investment window in mind, so recent ebbs and flows have been more tumultuous, but if you are looking for an MMJ company that has continued to rise while others dropped off of the map, what I am seeing in this report is very promising.
Following are some excerpts that are very promising considering where they were 4 years ago:
They still have a very nice balance in the bank. They had $ 8,000 when I first started studying the company, so $ 2,864,251 in the bank as of this 10Q is a nice war chest.
Cash and cash equivalents at end of the Period:
Feb. 2018 Feb. 2017
$ 2,864,251 $ 567,217
The fact they are finally paying salaries is promising:
"During the six months ending February 28, 2018, the Company paid $236,560 in salaries to 3 directors. Comparing to $31,400 in the six months ending February 28, 2017".
And seeing the High Throughput Screening noted as completed in a 10Q is great! This procedure is huge money for personalized treatments. Each of my allergy shots is a little over $ 1,000. Imagine if it was treating cancer via apoptosis and allowing patients to avoid chemo/radiation.
"High Throughput Screening
We have standardized the procedure of High Through Output Screening (HTS) for the detection of correlations between cannabinoid ratios, dosages and anti-tumor activity using a growing library of human cancer cell lines and creating an enlarged variety of Cannabis-based compounds. We examine the biological activity of these compounds on tumor cell lines of distinct tissue lineage and are creating highly valuable therapeutic data. We then screen of the most potent cannabinoid/natural extracts with/without the conjunction of standard chemotherapy".
We have talked about patents over time. I couldn't get the list to paste but they can be found at https://ih.advfn.com/p.php?pid=nmona&article=77116710 and I pasted their comments about patents below.
"Intellectual Property
Our success depends in significant part on our ability to protect the proprietary nature of our Product Prospects, technology, and know-how, to operate without infringing on the proprietary rights of others, and to defend challenges and oppositions from others and prevent others from infringing on our proprietary rights. We plan to continue to seek patent protection in the United States and worldwide for our proprietary technologies".
That is just my feelings based on my investment and time studying the company. I post this for those who have shown interest in my "homework" over time. If this is not of interest, I completely understand.
Take care, Jim
Why do you say that? Why did you use a different profile to say it?
Thanks, Jim
Where are you hearing this surfgreen? I know it is an estimated completion date, but the date hasn't changed per the posting below from https://clinicaltrials.gov/ct2/show/NCT02359123
Please share a link to where you are getting this info.
Thanks, Jim
Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cannabics Capsules as Treatment to Improve Cancer Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients- Pilot Study
Study Start Date : November 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : April 2018
Completion of the work being performed at Rambam Hospital will dictate when the results of the trials will be reported.
I feel your pain. My account is dropping by thousands of dollars a day. But unlike other companies that make claims but do not have much proof from governments or ministries of health that trials are being performed, CNBX actually has to wait for the patients to complete their trials before the results will be available.
The great thing about being invested in CNBX is also the tough thing about being invested in CNBX: Unlike some of the companies of late that are proving to be "snake oil salesman" that can release positive news anytime, CNBX is beholden to patients completing their trials.
2018 is a huge year because not only are trials winding up, but physicians are sending in biopsies, so use of CNBX, as well as trial results, should start to push CNBX news and pps upward.
Take care, Jim
I don't know of any other study coming out in April.
The other projects they are working on are attaining apoptosis using both pill and liquid forms of their products, high throughput studies of biopsies, and accepting biopsies from physicians to develop patient-specific treatments at any stage of cancer.
Keep in mind all of the cancer studies have various studies within them, as they are studying breast, brain, colon, and the various other cancers all at the same time. So news can be released for breast cancer one month, brain the next, etc.
If the April CACS report arrives and brings about a fresh batch of press releases, I am hoping that will nudge the pps higher.
Take care, Jim
Hi Irie,
If you follow the links to the products you posted, I think you will find all but one are marketed for ailments completely different than cancer, and the one that does mention cancer mentions it as "for support with tumors and other ailments related to cancer".
I have pasted your links below with each products name and descriptions of the products copied directly from their websites.
https://goo.gl/images/XvzDSx = Hemp Market Place’s 12 Hour Time Release Capsules. Benefits Include Anti-Inflammatory, Analgesic, Antioxidant, Anti-Convulsant, Anti-Enemic, Anti-Psychotic and Anxiolytic (reduce anxiety).
Result: Good for issues listed above, but not fighting cancer. Not a CNBX type product.
https://goo.gl/images/3wduwy = FlavRX CBD Capsules - Formulated with our proprietary Herbal Calming Formula, each capsule contains Tumeric, known for it’s powerful anti-inflammatory effects and strong antioxidant, along with other Adaptogen Herbs, Sour Jujube Seed, Schisandra Fruit, and increase an individual’s resistance to chemical, physical and biological stresses.
Result: Good for issues listed above, but not fighting cancer. Not a CNBX type product.
https://goo.gl/images/JJnchv = CBD ALIVE - Most of their product descriptions list being helpful for spasms, convulsions, tremors, endocrine disorders, anxiety, depression, psychosis and other mood disorders, and overall wellness. Also, to be twice the anti-inflammatory agent as THC and is used by many patients for muscle and joint pains. There is a THC Robust that is listed as recommended by many oncologists for support with tumors and other ailments related to cancer.
Result: Good for issues listed above, but at this time, they advertise helping ailments related to cancer, but not fighting cancer itself. Not a CNBX type product.
https://www.neocanna.com/ = NEOCANNA BI-LAYER CBD TABLET with benefits of treating Inflammation – Neuropathic Pain - Autoimmune disease – Energy regulation - Metabolism – Reproductive function
Appetite – Depression Anxiety – Even Cancer
Result: Good for issues listed above, but if they feel their product is made to fight cancer, they buried the lead and made it sound like "it might even fight cancer". Definitely not how CNBX is being developed or marketed. I see nothing on their website that links to clinicaltrials.gov or other sites or articles that would tie their product to fighting cancer or in development to do so.
Unlike above, this is what you find on Cannabic's website regarding directly treating cancer:
Cannabics: The main purpose in the treatment of patients with advanced cancer and CACS is to prolong life and to improve quality of life (QoL) as far as possible. Based on our in vitro research data cross-linked with clinical outcomes, we will create a state of the art cancer related diagnostic tool which will turn cannabinoids a therapy of choice in contemporary oncology. Our mission is to develop lab tests that will offer doctors and their patients a profile of personalized treatment with cannabinoids.
No mention of fighting depression, anxiety, tremors, inflammation, energy, reproductive function, etc, ailments which have all had a hundred or more pills on the market for years, so another would not be revolutionary like successfully treating cancer. It feels like the other products have put CBD and THC in a pill, thrown it at the wall, and hoped it sticks to something.
Cannabics has Rambam Hospital and Clinictrials.gov showing studies actually working to cure cancer and unlike the others, clearly says so, not just on their website, but in their studies, patent applications, government-funded research, etc.
Hope this helps explain why I felt CNBX led the pack back in 2014 and still does today.
Take care, Jim
I completely agree. I am hoping with what we have seen with the hiring of and presentation by the new VP of R&D that they are taking steps to start promoting the company more across the board.
As of late, it has simply been hung out to swing in the wind. Let's hope with everything they are doing that that is going to change!!!
Happy Easter!! Jim
Post a link to the news Matt!!
Thanks, Jim
Hi Surfgreen,
If by support you mean support from CNBX in the form of advertising, promotion, etc, I completely agree. Sending their VP of R&D to Canna-Tech is the first and biggest form of support I have seen in quite awhile if not ever.
Support has been questioned before, and in the past, the CEO has made statements along the lines of "We are scientists, not promoters. We let the SEC filings speak for themselves".
I am hoping that speaking at Canna-Tech is a sign that, with a number of big accomplishments pending for the company, that they are going to start promoting themselves more.
Hi Irie,
I will post your questions and address each individually.
Q: "There has been talk of CNBX patents and pending patents adding massive value to the company. Have they talked about how the patents will add value?"
A: The new patents are for personalized treatments. The main drive (and added value) of obtaining the new patents are for patenting methods of testing that will allow for personalizing which cannabinoids or combinations of cannabinoids are effective in individual patients.
You will have blood drawn and medication created to treat your exact issues, not just be prescribed a catch-all prescription or treatment. An area to compare this to is the treatment of allergies. Instead of just prescribing prescription level Claritin, allergists draw blood and create serums specific to a patients allergies, give injections over time, raising the level of the allergens being treated, and give a personalized instead of generic treatment.
Q: "Has there been any interest from external companies or markets in any of the patents?"
A: YES!!! Personalized cancer treatments have been the goal of many companies, but particularly of major hospitals that partner with manufacturers to create their own studies and find ways to personalize treatment.
Mega Hospitals are the new big pharma. They partner with their governments to perform studies and create treatments and then sell the products to companies like Merck, etc to distribute. Studies like these help fund the hospitals and in turn fund further studies of other ailments. For a review of just such studies, see the link below, which is a hospital/multi-government partnership:
https://clinicaltrials.gov/ct2/show/NCT02359123
I am in a study like this myself. I have been being treated for allergies in this way the last couple years, and a lot of my costs have recently been picked up in a partnership between the manufacturers and hospital because they want to use my results in their studies. My agreement is between my hospital, my medical provider (allergist), and the manufacturer of the products they are giving me (ie, like a CNBX). Each shot I receive would have cost me over $ 1,000 at 13 shots a month, but instead, I am paying for just the office visits, and even they are greatly reduced to around $ 10 every 4 months.
Q: "Will they try to develop pharmaceuticals themselves?" Cannabics is continually developing new pharmaceuticals, in addition to the ones they already have. Serums and pills both.
Q: "I have heard of multiple time release cbd capsules on the market. Do they have a patent for their time release capsule?"
A: If they are on the market, my guess is they have a patent or patent pending. Cannabics first long release pills have been on the market since late 2014 and have all been under patent.
If you could, please provide me links to these other time released capsules and I will review them.
Remember that Cannabics does not put their name on their pills, so products you see like the WANA Brands, Wana Caps, etc are actually Cannabics products with a different name/branding.
I do not know of any long release pill manufacturer that has had the track record Cannabics (and Rambam Hospital in Israel where they test their products) have had in the long release pill sector, but I would be happy to look and compare if you can provide links.
Q: "What is the profit catalyst that would drive this s/p to $20 as you’ve stated in the past?"
A: While I typically talk research and findings instead of share prices, my statement about CNBX being anticipated to go to around $ 20 or more once the US and International patents are in for personalization is based on what other products went to when their patents came in.
The stock price of GWPH for example, which uses a 4-hour oral spray instead of 12-hour long release pill, skyrocketed, and their stock closed yesterday at $ 110 pps. With being a 4-hour spray instead of a 12-hour pill, their product is inferior in my opinion due to the workplace and acceptance/convenience implications I have stated in previous posts, but their stock skyrocketed just the same.
Get with me if you have further questions. I have pasted one of the links below that discusses personalization.
Take care, Jim
https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-files-an-international-patent-application-on-methods-for-testing-and-predicting-therapeutic-effectiveness-of-cannabinoids-for-cancer-patients-667671863.html
It appears the entire sector was green today! All of my MMJ closed green, a nice color to see splashed across the listings.
Now to get some of these back to where they should be.
April = The results of the 2-year CNBX study covered by clinicals.gov.
The various CNBX patents should be hitting the news as the weather turns warmer.
And the federal government finally gave us back to back good news regarding US regulation.
With so many positives circling, I am hoping this makes for a hot summer, if not before!
Take care, Jim
A HUGE Double Smack to Jeff Sessions and all he has been trying to do to us!!!
We are not completely there, but this and the recent "RIGHT TO TRY" legislation that passed the House are very positive extensions of Obama Era MMJ protections and even a new level of protection with Right to Try!!! Great news going into April!!! Link to article below excerpt below:
President Trump Signs Bill Extending Federal Medical Marijuana and Hemp Protections
Emily Watkins March 23, 2018
President Trump has officially signed into law an omnibus spending package which includes an extension of federal protections for state-level medical marijuana and hemp laws.
The spending bill, which funds the government through the end of September, extends the Rohrabacher-Blumenauer amendment. The amendment, first approved in 2014, prevents the Department of Justice (including the DEA) from spending any federal funds to enforce federal marijuana laws in states that have legalized the plant for medical use. The spending bill would also extend a law that protects state laws that allow hemp to be grown for research purposes.
“We are very pleased to see that neither Congress nor the White House bent to the will of Attorney General Jeff Sessions when it comes to his anti-marijuana crusade,” says Justin Strekal, Political Director of NORML. “There are thirty states that have authorized the use of medicinal cannabis, serving over two million patients nationwide who rely on these programs. At a time when the majority of states now regulate marijuana use, and over six out of ten voters endorse outright legalizing the plant’s use by adults, it makes no sense from a political, fiscal, or cultural perspective to allow Sessions to attempt put this genie back in the bottle.”
Although this is good news, Representative Earl Blumenauer says; “While I’m glad that our medical marijuana protections are included, there is nothing to celebrate since Congress only maintained the status quo. These protections have been law since 2014. This matter should be settled once and for all. Poll after poll shows that the majority of Americans, across every party, strongly favor the right to use medical marijuana.”
He continued, “Instead, Attorney General Jeff Sessions is doubling down on the failed War on Drugs and Republican leadership in Congress—led by Chairman Pete Sessions—is stonewalling. They’re ignoring the will of the American people by blocking protections for state adult-use laws and cannabis banking. They even refused our veterans access to lifesaving medicine.
Below is the full text of the Rohrabacher-Blumenauer amendment:
None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.
https://themarijuanaherald.com/news/president-trump-signs-bill-extending-federal-medical-marijuana-and-hemp-protections/
A HUGE Double Smack to Jeff Sessions and all he has been trying to do to us!!!
We are not completely there, but this and the recent "RIGHT TO TRY" legislation that passed the House are very positive extensions of Obama Era MMJ protections and even a new level of protection with Right to Try!!! Great news going into April!!! Link to article below excerpt below:
President Trump Signs Bill Extending Federal Medical Marijuana and Hemp Protections
Emily Watkins March 23, 2018
President Trump has officially signed into law an omnibus spending package which includes an extension of federal protections for state-level medical marijuana and hemp laws.
The spending bill, which funds the government through the end of September, extends the Rohrabacher-Blumenauer amendment. The amendment, first approved in 2014, prevents the Department of Justice (including the DEA) from spending any federal funds to enforce federal marijuana laws in states that have legalized the plant for medical use. The spending bill would also extend a law that protects state laws that allow hemp to be grown for research purposes.
“We are very pleased to see that neither Congress nor the White House bent to the will of Attorney General Jeff Sessions when it comes to his anti-marijuana crusade,” says Justin Strekal, Political Director of NORML. “There are thirty states that have authorized the use of medicinal cannabis, serving over two million patients nationwide who rely on these programs. At a time when the majority of states now regulate marijuana use, and over six out of ten voters endorse outright legalizing the plant’s use by adults, it makes no sense from a political, fiscal, or cultural perspective to allow Sessions to attempt put this genie back in the bottle.”
Although this is good news, Representative Earl Blumenauer says; “While I’m glad that our medical marijuana protections are included, there is nothing to celebrate since Congress only maintained the status quo. These protections have been law since 2014. This matter should be settled once and for all. Poll after poll shows that the majority of Americans, across every party, strongly favor the right to use medical marijuana.”
He continued, “Instead, Attorney General Jeff Sessions is doubling down on the failed War on Drugs and Republican leadership in Congress—led by Chairman Pete Sessions—is stonewalling. They’re ignoring the will of the American people by blocking protections for state adult-use laws and cannabis banking. They even refused our veterans access to lifesaving medicine.
Below is the full text of the Rohrabacher-Blumenauer amendment:
None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.
https://themarijuanaherald.com/news/president-trump-signs-bill-extending-federal-medical-marijuana-and-hemp-protections/
A HUGE Double Smack to Jeff Sessions and all he has been trying to do to us!!!
We are not completely there, but this and "RIGHT TO TRY" are very positive extensions of Obama Era MMJ protections and even a new level of protection with Right to Try!!! Great news going into April!!! Link to article below excerpt below:
President Trump Signs Bill Extending Federal Medical Marijuana and Hemp Protections
Emily Watkins March 23, 2018
President Trump has officially signed into law an omnibus spending package which includes an extension of federal protections for state-level medical marijuana and hemp laws.
The spending bill, which funds the government through the end of September, extends the Rohrabacher-Blumenauer amendment. The amendment, first approved in 2014, prevents the Department of Justice (including the DEA) from spending any federal funds to enforce federal marijuana laws in states that have legalized the plant for medical use. The spending bill would also extend a law that protects state laws that allow hemp to be grown for research purposes.
“We are very pleased to see that neither Congress nor the White House bent to the will of Attorney General Jeff Sessions when it comes to his anti-marijuana crusade,” says Justin Strekal, Political Director of NORML. “There are thirty states that have authorized the use of medicinal cannabis, serving over two million patients nationwide who rely on these programs. At a time when the majority of states now regulate marijuana use, and over six out of ten voters endorse outright legalizing the plant’s use by adults, it makes no sense from a political, fiscal, or cultural perspective to allow Sessions to attempt put this genie back in the bottle.”
Although this is good news, Representative Earl Blumenauer says; “While I’m glad that our medical marijuana protections are included, there is nothing to celebrate since Congress only maintained the status quo. These protections have been law since 2014. This matter should be settled once and for all. Poll after poll shows that the majority of Americans, across every party, strongly favor the right to use medical marijuana.”
He continued, “Instead, Attorney General Jeff Sessions is doubling down on the failed War on Drugs and Republican leadership in Congress—led by Chairman Pete Sessions—is stonewalling. They’re ignoring the will of the American people by blocking protections for state adult-use laws and cannabis banking. They even refused our veterans access to lifesaving medicine.
Below is the full text of the Rohrabacher-Blumenauer amendment:
None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.
https://themarijuanaherald.com/news/president-trump-signs-bill-extending-federal-medical-marijuana-and-hemp-protections/
It will make "Right To Try" federally legal and the states can choose to legislate differently if they oppose it.
The federal government is not taking that right away but instead providing a floor level law to allow it if the state agrees to.
Since most states currently have no "Right to Try" legislation one way or the other, it will basically be legal unless a state chooses otherwise.
As we are taking drugs that were previously not legally available federally and making them available, this is a great first step towards some of our goals! My guess is this will quickly give way to patients who have dangerous and debilitating seizure issues, etc.
Below is the link to Right To Try's Q&A and below that is an excerpt from righttotry.org:
http://righttotry.org/wp-content/uploads/2017/01/RTT-FAQ_QA.pdf
Question: The FDA controls drug approval, and it trumps state law. How can states legally do this?
Answer: It is well established that the U.S. Constitution was designed to provide a floor of protection for individual rights, not a ceiling. States may provide additional and greater protections of individual rights—and all of them do.
For instance, many states protect free speech rights to a greater extent than the U.S. Constitution, others provide greater privacy rights. While the Supreme Court has never addressed Right To Try
specifically, it has held that states have great latitude in regulating health and safety, including medical standards, which are primarily and historically protected as a matter of local concern.
The Supreme Court has recognized a state’s power to govern the practice of medicine involving terminal patients. For example, in Gonzales v. Oregon, the Court upheld the state’s “right to die” law, enacted by Oregon voters, over the objections of the U.S.
Attorney General, who argued that federal law preempted the state law. Considering the Supreme Court deferred to a state’s authority to protect a person’s right to die, it would be consistent for the Court to protect a patient’s right to try to save his own life.
In Abigail Alliance v. Von Eschenbach, a three-judge panel found that the due process clause of the 5th Amendment guaranteed terminally ill patients’ access to investigational treatments that had passed FDA Phase I safety testing. However, upon a request by the FDA for a rehearing by the full court, that ruling was reversed. That decision is not binding on any other federal court outside the D.C. Circuit. Most important, it did not involve the same scenario presented by Right To Try, including the fact that no state law protecting access to investigational drugs was in place at the time.
Great quarterly layout. Thank you so much surfgreen!
When is that and what do you anticipate the effect on share price to be?
I am asking for DD as I do DD for CNB* so kind of asking others to share as I do rather than add to my homework load.
Thank you for your time!! Jim
To those that have read my posts, you know I give straightforward info with links supporting my info. I have not had the chance to research OWCP as I have other stocks.
Does anyone here have any data available on whether OWCP is going to have anything positive going on in the next 3 to 6 months and if so provide links to support the info.
Thank you for your time! Jim
"Right To Try" Law passes House Wednesday Evening:
https://www.politico.com/story/2018/03/21/drugs-right-to-try-congress-434677?cid=apn
Hi Surfgreen,
Not seeing anything from yesterday's Canna-Tech yet, but yes, the clinical trials are listed as being on track for release in April.
You can always get the latest news on CNBX by entering their name at ClinicalTrials.gov.
Take care, Jim
Thank you for your kind words. I take it you have followed the clinical trial reports over the past couple years that list the results of the participants in the trials. (The 100% apoptosis success, the high throughput process that speeds testing the biopsies and treatment, etc).
I do not claim to be a doctor or financial advisor, but since you are claiming to be a specialist in law, allow me to provide you the information available from ClinicalTrials.gov, the SEC, and various reports that show the results that will hopefully keep me a free man.
https://clinicaltrials.gov/ct2/show/NCT02359123
SEC Filing regarding CNBX findings:
https://seekingalpha.com/filing/3358772
Apoptosis Findings:
http://www.spjnews.com/2016/12/cannabics-announces-specific-ratios-of-cannabinoids-led-to-apoptosis-in-md-mb-231-breast-cancer-cell-viability/
https://www.reddit.com/r/weedstocks/comments/5v8jyv/cnbx_cannabics_pharmaceuticals_inc_dd/
Yet another clinical study:
https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-announces-start-of-clinical-study-in-israel-for-cancer-patients-300239495.html
https://fintel.io/b/17484-cnbx-cannabics-pharmaceuticals-stock-analysis-and-research-report
Canna-Tech is still going on right this minute. Dr. Grinberg is still there discussing CNBX with the venture capitalists and others interested in the field as I type.
People that may take an interest in CNBX based on what they are seeing at Canna-Tech have not even had a chance to leave and make it back to their checkbooks.
I have worked conventions like this for years. You make new contacts, take their materials with you, review your options (probably with a board of people), and buy in accordingly.
The effects of Canna-Tech were not going to be visible at the same time the convention is taking place. Give it time to see who takes an interest.
All things Canna-Tech - CANNATECH DAY 1: For anyone that questions whether Canna-Tech is a big deal in the medical industry, as well as cannabis industry, here are links and videos to explain what is happening today and tomorrow. Following that is a New York Times article on CNBX/Grinberg, video of Canna-Tech, etc.
Pasted from the first link below, here is CNBX's Dr. Moran Grinberg's listing in the attendee agenda. She is speaking Tuesday at 1:50pm Tel Aviv local time.
"Bringing Personalized Cannabinoid-based Medicine to the World Tel Aviv Moran, VP of R&D represents the first and only company in the world to bring personalization of cannabinoids in cancer treatment (which is also dedicated to preventing cancer onset in healthy adults and progression in patients.) Moran’s presentation will discuss the development of cancer diagnostics tools in conjunction with cannabinoid medicine".
https://www.canna-tech.co/tlv-2018-agenda/
Here is a video to sell you on Cannatech!!!
Hi bigfred1,
Glad you liked the info and I hope Wana can put you into a cap that helps more than your current meds.
You might want to reach out to Wana, explain the issues you are having, share any allergies you may have, and see if they can advise which to go with. I chatted via email with co-owner Nancy at Wana 2 or 3 years back and she is fantastic.
I agree with what you said about Sessions and the near future. Here are the overall points to keep in mind about CNBX compared to all other products in the near and distant future:
1. They are the ONLY product to have 100% apoptosis in every cancer tested and every patient tested (brain, breast, you name it, all cancers, all patients). Their product kills cancer without damaging other cells and does it like a boss.
2. They are the only long release pill of their type that has the studies to back up their effectiveness and be more Human Resources friendly. One of my masters is in Human Resources (HR) and I spent years as a head of training, safety, and HR. The next battle after legalization is what companies will allow brought onto their property and what products are most easily accepted by the public.
GWPH is trading at $ 118 and their spray lasts 4 hours. So you have to take it to work with you. If you spill it, it leaks out into your cubicle, etc, you have an HR nightmare. Leave it in your car and the heat or cold affect its strength. With CNBX, you take it before work and after work. No HR issues.
3. I am getting older, so I suppose I have to stop using "Grandma" references in a few years, but I always refer to "What will grandma most easily accept when her doctor starts recommending medical marijuana"? Will she be more apt to accept a spray, a cookie, a brownie, or a pill that she takes just like every other pill? CNBX is more like traditional medicines than most MMJ products and in turn will be much more readily accepted.
What do I mean by mentioning these points? It may not all happen in March or April 2018, but in the not too distant future, the final results will be in, the patents will be finalized, the various pills will be much easier for physicians to push, and with the biopsy service, CNBX may just be what cures or greatly reduces cancer.
Now, will it be called "Cannabics" at that time? Perhaps they will get bought out by a "big pharma" like Merck, etc and go by a different name, but even if that buyout price is 1/4 of GWPH, the price will be around $ 30 per share, and that is a great investment to be sitting on.
I started my homework on CNBX in 2014, started buying in in 2015, and it has been a huge change in my life, and I see this being just the beginning.
Take care, Jim
As for when CNBX will get product to market: Cannabics capsules have been on the market the last few years under the name Wana Caps.
Below are a few links to various sites discussing the caps:
https://www.wanacaps.com/home
https://supplementpolice.com/wana-caps/
http://www.marketwired.com/press-release/cannabics-pharmaceuticals-announced-the-launch-of-wanacaps-xr-in-colorado-otc-pink-cnbx-2031783.htm
http://www.marijuanatimes.org/wana-caps-slow-release-cannabis-capsules/
Patient-Specific Treatments: Just like you can go to an allergist and have a serum specific to your allergies made and injected, here is info on CNBX’s work in that area. You can see links regarding the fact they accept biopsies from physicians so as to create patient-specific treatments below. Treatment of these biopsies has shown 100% apoptosis, which means their product kills cancer without damaging healthy cells, a huge jump forward over radiation and chemotherapy:
https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/cannabics-pharmaceuticals-specific-ratios-cannabinoids-apoptosis-mda-mb-231-breast-cancer-cell-viability/
SEC Filing covering this info:
https://seekingalpha.com/filing/3358772
https://unitedpatientsgroup.com/blog/2017/07/20/Apoptosis-Cancer-Cannabinoids
Also, they are running international studies via numerous government entities. These can be tracked at the following government website:
https://clinicaltrials.gov/ct2/show/NCT02359123
Get with me if you need more info.
Take care, Jim
As for when CNBX will get product to market: Cannabics capsules have been on the market the last few years under the name Wana Caps.
Below are a few links to various sites discussing the caps:
https://www.wanacaps.com/home
https://supplementpolice.com/wana-caps/
http://www.marketwired.com/press-release/cannabics-pharmaceuticals-announced-the-launch-of-wanacaps-xr-in-colorado-otc-pink-cnbx-2031783.htm
http://www.marijuanatimes.org/wana-caps-slow-release-cannabis-capsules/
Patient-Specific Treatments: Just like you can go to an allergist and have a serum specific to your allergies made and injected, here is info on CNBX’s work in that area. You can see links regarding the fact they accept biopsies from physicians so as to create patient-specific treatments below. Treatment of these biopsies has shown 100% apoptosis, which means their product kills cancer without damaging healthy cells, a huge jump forward over radiation and chemotherapy:
https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/cannabics-pharmaceuticals-specific-ratios-cannabinoids-apoptosis-mda-mb-231-breast-cancer-cell-viability/
SEC Filing covering this info:
https://seekingalpha.com/filing/3358772
https://unitedpatientsgroup.com/blog/2017/07/20/Apoptosis-Cancer-Cannabinoids
Also, they are running international studies via numerous government entities. These can be tracked at the following government website:
https://clinicaltrials.gov/ct2/show/NCT02359123
Get with me if you need more info.
Take care, Jim
I've wondered why they would take the million shares at $ 2 when I think they could have picked up that many shares at less than $ 2 over the past month, etc.
Canna-Tech next week will be interesting. Get us in front of some VC's and see what comes of it. The company and its products are top notch from top down. The main thing that keeps hampering us is every time we start a run, some idiot like AG Sessions opens his mouth and kills the run while not actually doing anything that he claims.
This is bigger than all of that. So will be interesting to see how it plays out. The VC should buy more, but not sure they will wait till May.
Take care, Jim
I know at one time OWC was considered the best structured of any of the MMJ companies. I have not stayed up with it to know if that is still the case.
I had been advised to pick some up back when it was $ 1.60 and when I liquidated out of a longterm investment (Lionsgate Films when they split their stock) I bought some OWC.
The entire sector seems to be taking a continual beating, in large part due to Jeff Sessions threatening to crack down on MMJ every month or so even though Trump ran on a state's rights/pro-MMJ platform.
I have continued to hold as it would not yield enough money to justify selling off at a loss at this point. I am more heavily invested elsewhere in the sector and my research since 2014 is there. Canna-Tech next week will hopefully bring the sector a boost.
Take care, Jim
Cherry, your message "Because OWC is clean and had NOTHING to do with JF. Scam" was the clarification I was referring to.
Take care, Jim
ViaDerma was a sponsor for Super Bowl 52 "SB52 Big Game Experience" held during Superbowl weekend in Minneapolis, organized by The Brewer Group, a marketing, media and consulting firm founded by former NFL player, Jack Brewer.
I went to the site to confirm, and sure enough, at the bottom of each event, there are sponsor logos and ViaDerma is one of them.
Here is the link:
http://superbowl.brewer-media.com/
Take care, Jim
I was asking for clarification of the post, which Cherry has since clarified in a private message.
The law and perception can be two separate things, and perception can sometimes make or cost more when it comes to the fluctuation of stocks. I was asking clarification of Cherry's opinion.
On a side note: Where are you finding lawyers that let you into the office for $ 25? Most start at $ 450 an hour with a minimum of 1 hour billed per visit unless working via a retainer.
Take care, Jim
Are you saying it is fantastic news because this will "reset" OWCP and allow it to start making money again?
Just trying to confirm the upside and that is the main one I could think of.
Thank you, Jim
Well, I didn't want to seem a know it all... ;)
Thank you Scuba2. I wouldn't normally have shared so much about myself but I figured I should explain my background and why I am heading into my fourth year of researching CNBX and the MJ and MMJ sector and three years invested in CNBX.
I am the guy that used to write policies regarding what you could bring to work and CNBX really did and still does jump out at me as the most HR friendly product of its kind, the "next fight" in my opinion once legality is no longer an issue.
I know the OTC Market is a bit of a "Wild West" place to invest, but in this case, I think this product has a ton of examples of it being legitimate and having a huge future.
Thank you for your kind words and Go CNBX for us all!
Take care, Jim
Why CNBX Is Bigger Than Sector Right Now:
I know the sector has had a rough run as of late and a lot of times, as the sector goes, CNBX goes.
Here is why CNBX is above the rest of the sector going into summer:
1. CNBX's Dr. Moran Grinberg, VP of R&D, speaking as a keynote speaker at the Annual Canna-Tech Conference to be held in Tel-Aviv, Israel, March 19th-20th for the Session "Bringing Personalized Cannabinoid-based Medicine to the World".
WHY IS THIS BIG?
Canna-Tech brings together investors and specialists in the MJ and MMJ world and CNBX has never had this kind of exposure at such a conference. You want a major investor to hear about and fall in love with CNBX? This is the kind of situation that makes that happen. Whether it is a Bill & Melinda Gates type private organization that wants to cure cancer or Big Pharma, this is where you want to be seen. Link to Yahoo Finance coverage below.
https://finance.yahoo.com/news/cannabics-dr-moran-grinberg-speak-194600261.html
2. April 2018 - Capsules Study Due In April 2018.
WHY IS THIS BIG?
This report has been a couple years in the making and is being tracked not by some do it yourself PR page but by Clinical Trials.Gov. This is not "news", this is various governments telling you that this is really happening and some of the specifics of the study pre-report. Here is the link: https://clinicaltrials.gov/ct2/show/NCT02359123
3. March 2018 - There is talk of other studies becoming available this month. I do not have specific links as far as on what but this has popped up in writings about CNBX, so something is a brewing as early as this month.
4. January 2018 Cannabinoid International Patent Application:
WHY THIS IS IMPORTANT:
It takes months to get patent approval but CNBX has numerous patents, both US and International, in the works. This is big because when these patents becoming a done deal, the news will greatly help solidify CNBX with investors and push CNBX in front of people.
I have read that some feel the patents will make CNBX jump to around $ 20 based on how other OTC stock companies performed when their patents came in. I do not typically talk dollar amounts, sticking to known facts instead, but I wanted to explain why a patent can suddenly be of so much interest in terms of investors, news, belief in the company's solidity, etc. Here is the link to the January Patent News:
https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-files-an-international-patent-application-on-methods-for-testing-and-predicting-therapeutic-effectiveness-of-cannabinoids-for-cancer-patients-667671863.html
5. November 2017 - Patent for Cannabinoid Modulation of the Microbiome.
WHY IS THIS IMPORTANT?
Same thing, different patent. The more patents CNBX holds for its various products and processes, the better, as it solidifies the company. Here is the link:
https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-files-patent-application-on-cannabinoid-modulation-of-the-microbiome-656114393.html
6. September 2017 - US Patent - Cannabics announced today it has filed an extensive provisional patent application with the US Patent & Trademark Office (USPTO) on a new Method for Sensitivity Tests of Cannabinoids on Patient-Derived Tumor Biopsies and CTCs.
WHY IS THIS IMPORTANT?
In this case, a US Patent no less. Again, the more patents for products and processes, filed in more countries as is appropriate, the better. Here is the link:
https://www.thestreet.com/story/14295507/1/cannabics-pharmaceuticals-files-a-patent-application-for-sensitivity-tests-of-cannabinoids-on-patient-derived-tumor-biopsies-and-ctcs.html
7. August 2017 Positive Report Regarding Patent Application which means the patent office saw novelty of product and process.
WHY IS THIS BIG?
This is a report showing that CNBX's products and patents are being reviewed and initial findings are greatly in CNBX's favor as far as the products and patents being novel (unlike other products or processes filing for patents or on the market).
The patent process is a long one, and to get a glowing report like this midway through is a huge confidence booster that other companies that are also submitting secret processes, etc do not have products/processes like CNBX.
I was told a while back by an IHubber that a ton of MMJ companies already have CNBX style products and have them already beat. This report completely blows concerns like that out of the water. The patent office would not give such a glowing report if novelty did not exist. Here is the link:
https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-received-positive-report-from-the-patent-cooperation-treaty-regarding-cannabinoid-personalized-screening-of-cancer-cells-300510252.html
A bit about me: I spent 2002 to 2017 as a Chief Operations Officer. Before that, as the head of Training, Human Resources, and Safety for 7 automotive plants.
I have a BA in Psychology and Masters in Adult Education, Workforce Education, Program Planning, Administration, and most importantly for us here, Human Resources. I stress Human Resources (HR) because in 2014 I started studying what MMJ products would be most HR friendly once MMJ became legal.
After legalization, the next hurdle is company HR policies, because just because a product is legal doesn't mean a company has to allow it on their property, even for medicinal purposes.
CNBX 12 hour long release tabs jumped out at me as the most like traditional medicine, and therefore the easiest for everyone from your grandmother to your employer to accept as medicine. GWPH's spray lasts 4 hours, and what if it leaks in a purse for example? Now you have a mess of an MMJ product all over a cubicle as it drips out the bottom, etc. Take CNBX before work and when you get home and you are covered.
I made enough on CNBX in 2016 to offer myself up as a cost save to the company in early 2017, agreeing to hold a COO Emeritus position in case they need me to drop in and answer questions regarding my years of service (which I gladly do about 1 day a week and by email). I, of course, walked away with some perks and benefits, but the main perks are my chance to spend time with my family and continue to study where CNBX and other MMJ products will go.
I am hoping based on what I have seen since I started studying the market and in turn CNBX in 2014 that we will all make enough off of this stock to free ourselves up to live lives that are more driven by our own choices and not necessities.
I also hope the information above explains why, for myself, I consider CNBX to be a great investment. I do not profess to be an investment advisor in any way other than to share my opinions and research about my personal investing. In short, as many of us here say, these are just my opinions and research I have found and good luck to all!!!
Take care, Jim
A couple good 2018 articles:
https://seekingalpha.com/article/4141163-261-marijuana-stocks-jeff-slowed-us-32-percent-less-30-days-bad
https://seekingalpha.com/article/4144098-268-marijuana-stocks-learn-examination-event-dates-prior-52-weeks
In short, Sessions isn't affecting us long term and holding on MJ and MMJ is a good idea in 2018.
Take care, Jim
A couple good 2018 articles:
https://seekingalpha.com/article/4141163-261-marijuana-stocks-jeff-slowed-us-32-percent-less-30-days-bad
https://seekingalpha.com/article/4144098-268-marijuana-stocks-learn-examination-event-dates-prior-52-weeks
In short, Sessions isn't affecting us long term and holding on MJ and MMJ is a good idea in 2018.
Take care, Jim
A couple good 2018 articles:
https://seekingalpha.com/article/4141163-261-marijuana-stocks-jeff-slowed-us-32-percent-less-30-days-bad
https://seekingalpha.com/article/4144098-268-marijuana-stocks-learn-examination-event-dates-prior-52-weeks
In short, Sessions isn't affecting us long term and holding on MJ and MMJ is a good idea in 2018.
Take care, Jim